KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Thermo Fisher Scientific (TMO) EBIAT (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of EBIAT readings, the most recent being $1.7 billion for Q1 2026.

  • On a quarterly basis, EBIAT rose 9.6% to $1.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $6.9 billion, a 5.32% increase, with the full-year FY2025 number at $6.7 billion, up 6.09% from a year prior.
  • EBIAT hit $1.7 billion in Q1 2026 for Thermo Fisher Scientific, down from $2.0 billion in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $2.2 billion in Q2 2022 to a low of $1.3 billion in Q2 2023.
  • Median EBIAT over the past 5 years was $1.6 billion (2025), compared with a mean of $1.6 billion.
  • Biggest five-year swings in EBIAT: tumbled 41.8% in 2023 and later grew 13.66% in 2024.
  • Thermo Fisher Scientific's EBIAT stood at $1.6 billion in 2022, then increased by 4.57% to $1.6 billion in 2023, then rose by 11.18% to $1.8 billion in 2024, then increased by 7.65% to $2.0 billion in 2025, then dropped by 15.94% to $1.7 billion in 2026.
  • The last three reported values for EBIAT were $1.7 billion (Q1 2026), $2.0 billion (Q4 2025), and $1.6 billion (Q3 2025) per Business Quant data.